Skip to main content

Table 4 Clinical remission in JIA patients treated with DMARD according to treatment group. Prospective study results

From: Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach

  SDMARD alone
n = 33 (43%)
SDMARD combined
n = 6 (8%)
SDMARD BDMARD combined
n = 23 (30%)
BDMARD alone
n = 14 (18%)
Clinical remission
n = 76
p
Female sex a, n (%) 24 (73) 4 (67) 8 (35) 9 (64) 45 (59) 0.037
Persistent oligoarticular a, n (%) 19 (91) 6 (100) 4 (57) 2 (50) 31 (82) 0.048
ANA positivity a, n (%) 26 (79) 6 (100) 12 (52) 6 (43) 50 (66) 0.013
HLA B27 absence a, n (%) 31 (94) 0 12 (52) 8 (57) 57 (75) 0.005
Uveitis absence a, n (%) 27 (82) 2 (33) 21 (91) 13 (93) 63 (83) 0.006
Biologic DMARD a, n (%)
 Etanercept 0 0 5 (36) 10 (71) 15 (54) 0.040
DMARD dose tapering a, n (%) 29 (88) 3 (50) 14 (61) 11 (79) 57 (75) 0.050
  1. SDMARD Synthetic disease modifying drug, BDMARD Biologic disease modifying drug, JIA Juvenile idiopathic arthritis, n Number; ANA Antinuclear antibodies, HLA B27 Human leukocyte antigen, AE Adverse event; IQR Interquartile range, CR Clinical remission
  2. ap < 0,05 Statistically significant differences using the χ2 or Mann Whitney U tests